Valorphin TFA is a semisynthetic derivative of dihydrovaltrate with opioid analgesic activity

In vitro binding studies using brain homogenates from rat and guinea-pig indicate a preference for the mu-receptor site.?Bath application to cultured cerebellar Purkinje cells inhibited the spontaneous firing, similar to the effect seen with morphine.?Analgesic activity has been demonstrated in the hot plate and the tail flick test in the mouse and the Randall-Selitto test in the rat.?In the rhesus monkey valorphin was self-administered, but naloxone challenge induced only mild withdrawal signs.?Valorphin is a novel chemical entity, structurally not related to known opioids, which interacts preferentially with opiate mu-receptors[1].

T7666

C46H62F3N9O13

1006.03

Valorphin TFA(144313-54-2(free bas));Valorphin TFA(144313-54-2(free base))

[1]Maurer R , R?Mer D , H.H. Büscher, et al. Valorphin: A novel chemical structure with opioid activity[J]. Neuropeptides, 1985, 5(4-6):387-390.[2]Smith W D . A COMPARISON IN MICE OF NALOXONE AND NALORPHINE AS ANTAGONISTS TO NEUROLEPTANALGESIC DRUGS[J]. BJA: British Journal of Anaesthesia(11):11.

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years